MRI Radiomics-Based Prediction of Occult Sentinel Lymph Node Metastasis and D2-40 Expression in Breast Cancer

基于MRI放射组学的乳腺癌隐匿性前哨淋巴结转移和D2-40表达预测

阅读:1

Abstract

IntroductionPatients with Magnetic Resonance Imaging (MRI) axillary lymph node (ALN) negative in breast cancer may still have occult sentinel lymph node (SLN) metastases, which can influence clinical treatment strategies. This study aimed to develop an MRI-based radiomics model for predicting occult SLN metastases and D2-40 expression, and to investigate the intrinsic associations between D2-40 expression, SLN status, and related radiomics features.MethodsThis retrospective study included 141 MRI-diagnosed ALN-negative breast cancer patients from Center 1, randomly divided into training (n = 98) and validation (n = 43) sets (7:3 ratio). An independent external validation cohort (n = 40) from Centers 1 + 2 was established for model validation. Three logistic regression models were developed: (1) a clinical model, (2) a radiomics model, and (3) a clinic-radiomics nomogram, which predict SLN metastasis (Model 1) and D2-40 expression (Model 2). In addition, the correlation between D2-40 expression and SLN status was analyzed in this study using chi-square test. And the feature correlation between SLN radiomics model and D2-40 radiomics model and the strength of association between D2-40 and Model 1 features were assessed by Spearman and Pearson correlation analysis, respectively.ResultsThe nomogram outperformed the other models in both Model 1 (AUC: 0.821 validation/0.746 external) and Model 2 (AUC: 0.810 validation/0.645 external). D2-40 correlated with SLN status (P < .001). There were feature correlations between Model 1 and Model 2 features (Spearman) and between D2-40 and Model 1 features (Pearson).ConclusionsMRI-based radiomics features were effective in predicting occult SLN metastasis and D2-40 expression status in MRI ALN-negative breast cancers. An association was identified between D2-40 expression and SLN status, along with the corresponding radiomics features.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。